Exelixis Inc. President and CEOwarned that the company wasn't going to just sit on its cancer drug franchise, not with $2 billion in cash, equivalents and investments.
In the Sairopa deal, Exelixis will pay $40 million upfront and $70 million in near-term milestones for an exclusive, worldwide license to develop and sell Sairopa's ADU-1805. The drug is a monoclonal antibody targeting a protein — called signal regulatory protein alpha, or SIRPa — that protects cancer-associated proteins from being detected by the immune system's T cells and helps block the ability to clear tumor cells.
The moves were announced as Exelixis reported its third-quarter financials that showed the company with a $212.4 million profit through the first nine months of the year on revenue of nearly $1.19 billion.
South Africa South Africa Latest News, South Africa South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
An inside look into multi-family housing and the real estate market today - CEO SpotlightShakti C'Ganti, CEO, Ashland Greene Capital joins KRLD's David Johnson for this episode of CEO Spotlight.
Read more »
Exelixis puts fat wallet to work with Cybrexa, Sairopa deals - San Francisco Business TimesPresident and CEO Michael Morrissey said the deals tap the company's balance sheet and share risks with its partners.
Read more »
Ryan Rogers, grandson of Mary Kay Ash, appointed to CEO of cosmetic company - Dallas Business JournalRyan Rogers is following in the footsteps of his grandmother and company founder Mary Kay Ash and father Richard R. Rogers.
Read more »